SCHEDULE 13G/A: Laurence W. Lytton Amends Passive Stake in Evoke Pharma Inc to 3.9% via Warrants
Beneficial Ownership Disclosure
Laurence W. Lytton has filed an amended Schedule 13G, reporting beneficial ownership of 3.9% of Evoke Pharma Inc's common stock, primarily through warrants, as a passive investor.
Summary
- Laurence W. Lytton, a U.S. citizen, has filed an Amendment No. 2 to Schedule 13G regarding his beneficial ownership in Evoke Pharma Inc.
- The filing indicates beneficial ownership of 61,274 shares of Evoke Pharma Inc's Common Stock.
- These 61,274 shares consist entirely of warrants to purchase Common Stock.
- This stake represents 3.9% of the class of securities.
- The percentage is calculated based on 1,492,858 shares of Common Stock outstanding as of May 1, 2025, as reported by Evoke Pharma Inc in its Form 10-Q filed on May 13, 2025.
- Mr. Lytton holds sole voting power and sole dispositive power over all 61,274 shares.
- The securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: This is a routine regulatory filing (Schedule 13G) disclosing a passive ownership stake, which typically does not carry strong positive or negative sentiment regarding the company's operational performance or strategic direction.
Positives
- The disclosure of a significant individual investor, Laurence W. Lytton, holding a 3.9% stake in Evoke Pharma Inc, albeit passive, may signal a degree of investor confidence in the company.
Future Outlook
NA
Industry Context
This filing is a routine regulatory disclosure for a passive investor and does not provide specific insights into broader industry trends or competitive landscape beyond the fact that Evoke Pharma Inc is a publicly traded entity subject to SEC reporting requirements.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant individual investor's stake, which could be seen as a vote of confidence, though passive, in the company's long-term prospects.
Key Dates
| Date | Description |
|---|---|
| 03/31/2025 | Date of event which required the filing of this statement. |
| 05/01/2025 | Date as of which 1,492,858 shares of Common Stock were reported outstanding in Evoke Pharma Inc's Form 10-Q. |
| 05/13/2025 | Date Evoke Pharma Inc filed its Form 10-Q. |
| 05/15/2025 | Date of filing of this Schedule 13G Amendment No. 2. |
Keywords
Evoke Pharma Inc, Laurence W. Lytton, Schedule 13G, beneficial ownership, common stock, warrants, SEC filing, passive investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.